×
For best experience we recommend to activate Javascript in your browser.
Recombinant RSV (Palivizumab Biosimilar) antibody
Research Grade
Reactivity: Human
ELISA
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Product Details anti-RSV (Palivizumab Biosimilar) Antibody
(hide)
Target
See all RSV (Palivizumab Biosimilar) products
RSV (Palivizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for RSV (Palivizumab Biosimilar) antibodies
Mammalian Cells
Expression System
Mammalian cells
Clonality
All clonalities for RSV (Palivizumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for RSV (Palivizumab Biosimilar) antibodies
This RSV (Palivizumab Biosimilar) antibody is un-conjugated
Application
All applications for RSV (Palivizumab Biosimilar) antibodies
ELISA
Purpose
Palivizumab Biosimilar - Anti-RSV mAb
Characteristics
Antibody Type: IgG1-kappa
Purification
Recombinant antibody expressed in mammalien cells and purified.
Grade
Research Grade
Isotype
IgG1 kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Buffer
PBS pH 7.5
Storage
-80 °C
Storage Comment
store at -80°C
Target Details for RSV (Palivizumab Biosimilar)
(hide)
Target
RSV (Palivizumab Biosimilar)
Abstract
RSV (Palivizumab Biosimilar) Products
Target Type
Biosimilar
Background
MEDI-493, Synagis Palivizumab is a humanized monoclonal antibody of isotype IgG1k produced by recombinant DNA technology. It targets the epitope in the A antigenic site of the respiratory syncytial virus (RSV) F protein.
CAS-No
188039-54-5
Recently viewed
(hide)